首页> 外文期刊>EFSA Journal >Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
【24h】

Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

机译:根据1924/2006号法规(EC)第13(1)条,从红曲米中证实与monacolin K有关的健康主张并维持正常血液中的LDL胆固醇浓度(ID 1648、1700)的科学意见

获取原文
       

摘要

This opinion addresses the scientific substantiation of health claims in relation to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food that is the subject of the health claim is red yeast rice (i.e. rice fermented with the red yeast Monascus purpureus). The Panel considers that, whereas red yeast rice is not sufficiently characterised in relation to the claimed effect, the food constituent, monacolin K from red yeast rice, is sufficiently characterised. The claimed effects are “cholesterol” and “cholesterol management/heart health”. The target population is assumed to be adults in the general population. In the context of the proposed wordings, the Panel assumes that the claimed effect refers to maintenance of normal blood LDL-cholesterol concentrations. The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial physiological effect. In weighing the evidence, the Panel took into account that two randomised controlled trials provided from which conclusions could be drawn for the scientific substantiation of the claim showed an effect of red yeast rice preparations providing a daily dose of about 10 mg monacolin K on LDL-cholesterol 1 On request from the European Commission, Question No EFSA-Q-2008-2384, EFSA-Q-2008-2436, adopted on 30 June 2011. Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus L?vik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuh?user-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
机译:该意见涉及与来自红曲米的莫纳可林K有关的健康主张的科学依据,并维持了正常血液中LDL-胆固醇的浓度。科学依据是成员国在第13条健康声明综合清单中提供的信息,以及EFSA从成员国或直接从利益相关者那里获得的参考。健康声明的食物是红曲米(即用红曲霉红孢菌发酵的米)。小组认为,尽管就所要求的效果而言,红曲米尚无足够的特征,但红曲米中的食品成分莫纳可林K却有足够的特征。声称的作用是“胆固醇”和“胆固醇管理/心脏健康”。假定目标人群是普通人群中的成年人。在提议的措词中,小组认为所要求的作用是指维持正常血液中LDL-胆固醇的浓度。专家组认为,维持血液中低密度脂蛋白胆固醇的正常浓度是有益的生理作用。在权衡证据时,小组考虑到提供了两项随机对照试验,可以从中得出结论以对索赔进行科学证实,结果表明,每天提供约10毫克莫纳可林K的红曲米制剂对LDL-胆固醇1应欧洲委员会的要求,2011年6月30日通过,编号EFSA-Q-2008-2384,EFSA-Q-2008-2436。 Flynn,Ines Golly,Hannu Korhonen,Pagona Lagiou,Martinus L?vik,Rosangela Marchelli,Ambroise Martin,Bevan Moseley,Monika Neuh?user-Berthold,Hildegard Przyrembel,Seppo Salminen,Yolanda Sanz,Sean(JJ)Strain,Stephan Strobel, Inge Tetens,DanielTomé,Hendrik van Loveren和Hans Verhagen。

著录项

  • 来源
    《EFSA Journal》 |2011年第7期|共16页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 食品工业;
  • 关键词

  • 入库时间 2022-08-18 10:03:54

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号